ClinicalTrials.gov
public full text
Public Domain
A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)
This study will evaluate the efficacy and safety of brief induction therapy with a chemotherapeutic regimen containing MabThera, followed by either maintenance therapy with MabThera or no further therapy. The anticipated time on study treatment is 1-2 years, and the target sample size is 100-500 individuals.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Rituximab in Treating Patients With Follicular Non-Hodgkin's Lymphoma#834927
- Rituximab (anti-CD20 Monoclonal Antibody) As Single First-Line Therapy For Patients With Follicular Lymphoma With A Low Tumor Burden: Clinical And Molecular Evaluation#1148410
- Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma#252981
- Rituximab + Immunotherapy in Follicular Lymphoma#67886
- Monoclonal Antibody Therapy in Treating Patients With Follicular or Mantle Cell Lymphoma#859051
Record · ID 1095611
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive